MISONIX, INC. (NASDAQ:MSON) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01.
|
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
On February 10, 2017, Misonix, Inc. (the Company) received a
deficiency letter from The Nasdaq Stock Market LLC (Nasdaq)
indicating that the Company, as a result of not filing its
Quarterly Report on Form 10-Q for the fiscal quarter ended
December 31, 2016 (the Q2 10-Q) by February 9, 2017 and
disclosing that the Company will not be able to file the Q2 10-Q
within the five-day extension period provided in Rule 12b-25(b)
under the Securities Exchange Act of 1934, as amended, together
with its prior and ongoing failure to timely file its Quarterly
Report on Form 10-Q for the fiscal quarter ended September 30,
2016 (the Q1 10-Q), was not in compliance with Listing Rule
5250(c)(1) of the Nasdaq Listing Rules (the Rules) for continued
listing.
The Company has previously submitted a plan to Nasdaq to regain
compliance with the Rules and Nasdaq has granted the Company an
exception until March 13, 2017 to regain compliance. The Company
is required to submit to Nasdaq an update to the original
compliance plan not later than February 27, 2017.
At this time, this notification has no effect on the listing of
the Companys common stock on The Nasdaq Global Market.
The Company issued a press release on February 13, 2017 with
respect to the foregoing which is attached hereto as Exhibit
99.1.
| Item 9.01. | Financial Statements and Exhibits |
(d)Exhibits
| Exhibit No. | Description of Exhibit |
| 99.1 | Press Release dated February 13, 2017 |
About MISONIX, INC. (NASDAQ:MSON)
MISONIX, INC. (Misonix) is a surgical device company. The Company designs, manufactures and markets therapeutic ultrasonic products across the world for spine surgery, skull-based surgery, neurosurgery, wound and burn debridement, cosmetic surgery, laparoscopic surgery and other surgical applications. The Company’s products include BoneScalpel, BoneScalpel MIS System, SonicOne O.R. System and SonaStar. BoneScalpel is an ultrasonic cutting system with applications in orthopedic and reconstructive surgery, as well as neurosurgery. BoneScalpel MIS System offers deep cuts through osseous structures with minimal blood loss. Misonix SonicOne O.R. System is an ultrasonic surgical debridement system that allows surgeons to address the challenges chronic wounds present to them, the patient, and the health-care system. SonaStar is used for neurosurgical procedures, such as skull/non-skull base tumor resections, transnasal procedures and acoustic mengiomas. MISONIX, INC. (NASDAQ:MSON) Recent Trading Information
MISONIX, INC. (NASDAQ:MSON) closed its last trading session down -0.83 at 10.02 with 59,701 shares trading hands.
